Pfizer

Pfizer, a US-based Pharmaceutical Preparation Manufacturing company, reported its total carbon emissions as approximately 4.18 billion kg CO2e in 2024. This figure comprises about 616.8 million kg CO2e from Scope 1 emissions, around 513.5 million kg CO2e from Scope 2 (market-based), and approximately 3.56 billion kg CO2e from Scope 3 emissions. In the prior year, 2023, Pfizer's total emissions were approximately 4.92 billion kg CO2e.

Pfizer is committed to ambitious climate action, with several targets approved by the Science Based Targets initiative (SBTi). The company aims to achieve net-zero emissions across its entire value chain by 2040.

For near-term targets, Pfizer has committed to reducing absolute Scope 1 and Scope 2 GHG emissions by 46% by 2030, using a 2019 baseline. Furthermore, Pfizer plans to increase its annual sourcing of renewable electricity from 9% in 2019 to 100% by 2030. Within Scope 3, Pfizer is committed to reducing absolute emissions from business travel by 25% by 2025 and from upstream transportation and distribution by 10% by 2025, both from a 2019 baseline. The company also aims for 64% of its suppliers, by spend covering purchased goods and services, to have science-based targets by 2025.

For long-term goals, Pfizer aims to reduce its company GHG emissions (Scope 1 and 2) by 95% and its value chain emissions (Scope 3) by 90% from 2019 levels by 2040.